Managed Healthcare Executive Newsletter

Chemotherapy Remains Significant for Cancer Treatment

Chemotherapy may be the “boomer” to millennial-esque new cancer treatments, but there is a reason the old standard became that way, and isn’t likely to be replaced anytime soon.

Payers Should Take Action on Rising NSCLC Costs

A new report outlines the sharp cost increase associated with a NSCLC drug’s move from second-line to first-line treatment, and suggests payers work with manufacturers to address treatment pricing.

DIGITAL EDITION

Check out your December Issue

• State of the Industry Survey
• Managing Pain Drugs
• The Most Effective Healthcare Apps